295 related articles for article (PubMed ID: 30228001)
1. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
[TBL] [Abstract][Full Text] [Related]
6. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
[TBL] [Abstract][Full Text] [Related]
7. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
[TBL] [Abstract][Full Text] [Related]
9. Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
Koga H; Negishi M; Kinoshita M; Fujii S; Mori S; Ishigami-Yuasa M; Kawachi E; Kagechika H; Tanatani A
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759847
[TBL] [Abstract][Full Text] [Related]
10. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
[TBL] [Abstract][Full Text] [Related]
11. Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
Yang Y; Lv G; Xiu R; Yang H; Wang W; Yu P; Zhang J; Ye L; Wang H; Tian J
Eur J Med Chem; 2024 May; 271():116400. PubMed ID: 38626524
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor antagonists and anti-prostate cancer activities of some synthesized steroidal candidates.
Bahashwan SA; Al-Omar MA; Ezzeldin E; Abdalla MM; Fayed AA; Amr AG
Chem Pharm Bull (Tokyo); 2011; 59(11):1363-8. PubMed ID: 22041072
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
Xu X; Du Q; Meng Y; Li Z; Wu H; Li Y; Zhao Z; Ge R; Lu X; Xue S; Chen X; Yang Y; Wang J; Bian J
Eur J Med Chem; 2020 Apr; 192():112196. PubMed ID: 32169785
[TBL] [Abstract][Full Text] [Related]
15. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
Kandil S; Westwell AD; McGuigan C
Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862
[TBL] [Abstract][Full Text] [Related]
16. Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
He Y; Hwang DJ; Ponnusamy S; Thiyagarajan T; Mohler ML; Narayanan R; Miller DD
J Med Chem; 2021 Aug; 64(15):11045-11062. PubMed ID: 34269581
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
Wang A; Wang Y; Meng X; Yang Y
Bioorg Med Chem; 2021 Feb; 31():115953. PubMed ID: 33388655
[TBL] [Abstract][Full Text] [Related]
18. Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore.
Ochiai K; Yonezawa R; Fujii S
ChemMedChem; 2024 Mar; 19(6):e202400040. PubMed ID: 38291942
[TBL] [Abstract][Full Text] [Related]
19. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
[TBL] [Abstract][Full Text] [Related]
20. Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists.
Yamada A; Fujii S; Mori S; Kagechika H
ACS Med Chem Lett; 2013 Oct; 4(10):937-41. PubMed ID: 24900588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
